Physician profile
Tammy S Ho
NPI 1003179128
$5,404.40
in general payments reported to CMS, 2019-2025
36 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,081 · 2020: $169 · 2021: $310 · 2022: $884 · 2023: $762 · 2024: $975 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,961.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $928.98 | 2019-2023 | Ams 700 |
| Abbvie INC. | $759.37 | 2019-2025 | |
| Beckman Coulter, INC. | $389.44 | 2019 | |
| Astellas Pharma US INC | $288.81 | 2019-2024 | Myrbetriq, Xtandi |
| Sumitomo Pharma America, INC. | $252.75 | 2023-2025 | Gemtesa |
| Teleflex LLC | $241.57 | 2022-2025 | Urolift, Barrigel |
| Bluewind Medical | $230.16 | 2024-2025 | Revi |
| Allergan, INC. | $227.29 | 2019-2022 | |
| Axonics, INC. | $214.37 | 2022-2023 | Axonics |
| Tolmar, INC. | $185.02 | 2024-2025 | Eligard |
| Calyxo, INC. | $165.77 | 2024-2025 | Cvac Aspiration System |
| Antares Pharma, INC. | $152.11 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Merck Sharp & Dohme LLC | $151.96 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Urogen Pharma, INC. | $142.02 | 2022-2025 | |
| Laborie Medical Technologies Corp. | $127.33 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $122.17 | 2023-2025 | |
| Coloplast Corp | $115.90 | 2019-2024 | Titan |
| Immunitybio, INC. | $65.58 | 2024-2025 | |
| Halozyme INC | $62.94 | 2023 | |
| Aroa Biosurgery Incorporated | $61.62 | 2022-2023 | |
| C. R. Bard, INC. & Subsidiaries | $59.47 | 2022-2025 | Bard Urinary Drainage Bag |
| Integra Lifesciences Corporation | $48.90 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Bayer Healthcare Pharmaceuticals INC. | $48.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $41.89 | 2025 | |
| Urovant Sciences INC | $37.64 | 2021-2022 | |
| Femselect INC. | $37.31 | 2025 | Enplace |
| Tolmar Pharmaceuticals, INC. | $30.60 | 2022 | |
| Becton, Dickinson and Company | $28.46 | 2024 | Bard Urinary Drainage Bag |
| Endo USA, INC. | $26.50 | 2024 | Xiaflex |
| Palette Life Sciences, INC. | $26.47 | 2023 | |
| Ferring Pharmaceuticals INC. | $25.25 | 2024 | Adstiladrin |
| Endo Pharmaceuticals INC. | $24.42 | 2023 | Xiaflex, Aveed |
| Myovant Sciences INC. | $22.01 | 2021 | |
| Janssen Biotech, INC. | $21.82 | 2025 | Erleada |
| Pfizer INC. | $21.35 | 2022 | |
| Biotissue Holdings INC. | $18.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.